Call for US FDA official health claim for garlic

15 May 2005

A panel of international medical and scientific garlic experts convened at a recent cardiovascular symposium, held in Berlin, Germany, have concluded that there is enough evidence of the health benefits of garlic to warrant an official endorsement of the nutrient. The panel urged that a proposal for an official health claim should be submitted to the US Food and Drug Administration for review.

The team of experts was prompted by evidence derived from studies of garlic powder LI 111, developed by German firm Lichtwer Pharma and marketed as Kwai in Europe and in the USA by New York-based ABKIT. The panel said that, compared with other FDA health claims for substances such as soy, omega-3-fatty acids or oat bran, garlic and garlic powder LI 111 has a superior record for improving cardiovascular risk factors. The latter is backed by over over 42 clinical trials showing a benefit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight